Sarepta Therapeutics Inc (SRPT): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Sarepta Therapeutics ( SRPT) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.7%. By the end of trading, Sarepta Therapeutics fell 98 cents (-3.1%) to $30.73 on average volume. Throughout the day, two million shares of Sarepta Therapeutics exchanged hands as compared to its average daily volume of 2.5 million shares. The stock ranged in price between $30.64-$32.65 after having opened the day at $32.19 as compared to the previous trading day's close of $31.71. Other companies within the Drugs industry that declined today were: Somaxon Pharmaceuticals ( SOMX), down 13.1%, Synageva BioPharma ( GEVA), down 5.8%, Senesco Technologies ( SNT), down 5.3%, and Oxygen Biotherapeutics ( OXBT), down 5.2%.
  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of serious and life-threatening rare and infectious diseases. Sarepta Therapeutics has a market cap of $754 million and is part of the health care sector. Shares are up 4156.4% year to date as of the close of trading on Wednesday. Currently there are six analysts that rate Sarepta Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Sarepta Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and weak operating cash flow.

On the positive front, Cormedix ( CRMD), up 33.3%, Amicus Therapeutics ( FOLD), up 14.8%, Sucampo Pharmaceuticals Inc. A ( SCMP), up 11.5%, and Progenics Pharmaceuticals ( PGNX), up 8%, were all gainers within the drugs industry with Onyx Pharmaceuticals ( ONXX) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.